195 related articles for article (PubMed ID: 3167827)
1. An IgG3 monoclonal antibody established after immunization with GM3 lactone: immunochemical specificity and inhibition of melanoma cell growth in vitro and in vivo.
Dohi T; Nores G; Hakomori S
Cancer Res; 1988 Oct; 48(20):5680-5. PubMed ID: 3167827
[TBL] [Abstract][Full Text] [Related]
2. Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: requirements for tumor-associated antigen and immunogen.
Nores GA; Dohi T; Taniguchi M; Hakomori S
J Immunol; 1987 Nov; 139(9):3171-6. PubMed ID: 3668254
[TBL] [Abstract][Full Text] [Related]
3. Role of cell surface GM3 ganglioside and sialic acid in the antitumor activity of a GM3-based vaccine in the murine B16 melanoma model.
Gabri MR; Ripoll GV; Alonso DF; Gómez DE
J Cancer Res Clin Oncol; 2002 Dec; 128(12):669-77. PubMed ID: 12474053
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo antitumor effects of murine monoclonal antibody NCC-ST-421 reacting with dimeric Le(a) (Le(a)/Le(a)) epitope.
Watanabe M; Ohishi T; Kuzuoka M; Nudelman ED; Stroud MR; Kubota T; Kodairo S; Abe O; Hirohashi S; Shimosato Y
Cancer Res; 1991 Apr; 51(8):2199-204. PubMed ID: 1706961
[TBL] [Abstract][Full Text] [Related]
5. [GM3 ganglioside as melanoma specific antigen and its biological function].
Hirabayashi Y; Taniguchi M
Hum Cell; 1989 Mar; 2(1):63-9. PubMed ID: 2535260
[TBL] [Abstract][Full Text] [Related]
6. Analysis of melanoma antigen and its involvement in tumor-escape mechanisms.
Taniguchi M; Sakatsume M; Harada Y; Nores GA; Hakomori S
Princess Takamatsu Symp; 1988; 19():247-54. PubMed ID: 2978619
[TBL] [Abstract][Full Text] [Related]
7. Syngeneic monoclonal antibody against melanoma antigen with interspecies cross-reactivity recognizes GM3, a prominent ganglioside of B16 melanoma.
Hirabayashi Y; Hamaoka A; Matsumoto M; Matsubara T; Tagawa M; Wakabayashi S; Taniguchi M
J Biol Chem; 1985 Oct; 260(24):13328-33. PubMed ID: 2414279
[TBL] [Abstract][Full Text] [Related]
8. Immunocytochemical study on internalization of anti-carbohydrate monoclonal antibodies.
Kusano A; Ohta S; Shitara K; Hanai N
Anticancer Res; 1993; 13(6A):2207-12. PubMed ID: 8297135
[TBL] [Abstract][Full Text] [Related]
9. Immunization with a GM3 ganglioside nanoparticulated vaccine confers an effector CD8(+) T cells-mediated protection against melanoma B16 challenge.
Mazorra Z; Mesa C; Fernández A; Fernández LE
Cancer Immunol Immunother; 2008 Dec; 57(12):1771-80. PubMed ID: 18351335
[TBL] [Abstract][Full Text] [Related]
10. Cancer vaccines: an update with special focus on ganglioside antigens.
Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
[TBL] [Abstract][Full Text] [Related]
11. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T
Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687
[TBL] [Abstract][Full Text] [Related]
12. Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers.
Hoon DS; Wang Y; Sze L; Kanda H; Watanabe T; Morrison SL; Morton DL; Irie RF
Cancer Res; 1993 Nov; 53(21):5244-50. PubMed ID: 7916649
[TBL] [Abstract][Full Text] [Related]
13. Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship among avidity, effector functions, tumor targeting, and antitumor activity.
Chapman PB; Lonberg M; Houghton AN
Cancer Res; 1990 Mar; 50(5):1503-9. PubMed ID: 2105840
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human hexamer-dominant IgM monoclonal antibody to ganglioside GM3 for treatment of melanoma.
Azuma Y; Ishikawa Y; Kawai S; Tsunenari T; Tsunoda H; Igawa T; Iida S; Nanami M; Suzuki M; Irie RF; Tsuchiya M; Yamada-Okabe H
Clin Cancer Res; 2007 May; 13(9):2745-50. PubMed ID: 17473208
[TBL] [Abstract][Full Text] [Related]
15. Immunoreactivity of leukemic lymphoblasts of T-cell and B-cell precursor origin with monoclonal anti-GD3 and anti-GM3 antibodies.
Merritt WD; Sztein MB; Taylor B; Reaman GH
Leukemia; 1991 Dec; 5(12):1087-91. PubMed ID: 1774957
[TBL] [Abstract][Full Text] [Related]
16. Specificity and immunobiological properties of monoclonal antibody IMH2, established after immunization with Le(b)/Le(a) glycosphingolipid, a novel extended type 1 chain antigen.
Ito H; Tashiro K; Stroud MR; Orntoft TF; Meldgaard P; Singhal AK; Hakomori S
Cancer Res; 1992 Jul; 52(13):3739-45. PubMed ID: 1377598
[TBL] [Abstract][Full Text] [Related]
17. A novel hydrophobized GM3 ganglioside/Neisseria meningitidis outer-membrane-protein complex vaccine induces tumor protection in B16 murine melanoma.
Alonso DF; Gabri MR; Guthmann MD; Fainboim L; Gomez DE
Int J Oncol; 1999 Jul; 15(1):59-66. PubMed ID: 10375594
[TBL] [Abstract][Full Text] [Related]
18. Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells.
Livingston PO; Calves MJ; Natoli EJ
J Immunol; 1987 Mar; 138(5):1524-9. PubMed ID: 3805726
[TBL] [Abstract][Full Text] [Related]
19. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses.
Bolesta E; Kowalczyk A; Wierzbicki A; Rotkiewicz P; Bambach B; Tsao CY; Horwacik I; Kolinski A; Rokita H; Brecher M; Wang X; Ferrone S; Kozbor D
Cancer Res; 2005 Apr; 65(8):3410-8. PubMed ID: 15833876
[TBL] [Abstract][Full Text] [Related]
20. Complete antitumor protection by perioperative immunization with GM3/VSSP vaccine in a preclinical mouse melanoma model.
Gabri MR; Mazorra Z; Ripoll GV; Mesa C; Fernandez LE; Gomez DE; Alonso DF
Clin Cancer Res; 2006 Dec; 12(23):7092-8. PubMed ID: 17145833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
